Article info
PDFOriginal research
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
- Correspondence to Dr Stephanie Lheureux, Princess Margaret Hospital Cancer Centre, Toronto M5G 1Z5, Ontario, Canada; Stephanie.Lheureux{at}uhn.ca
Citation
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
Publication history
- Received March 18, 2023
- Accepted June 13, 2023
- First published June 28, 2023.
Online issue publication
October 18, 2023
Article Versions
- Previous version (7 August 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.